Source: Corporate Travel Management
The Market Online - At The Bell

Join our daily newsletter At The Bell to receive exclusive market insights

  • Corporate Travel Management (CTD) posts strong FY23 data pointing to a recovery from COVID years
  • However, the stock has been in the red all-day
  • The news leaves investors pondering what’s next, but the likely catalyst is a UK government contract
  • Corporate Management takes on liability for services on a floating barge in Dorset housing asylum seekers
  • CTD shares are down 7.67 per cent, trading at $17.94 at 2:12 pm AEST

Corporate Travel Management (CTD) has announced its results for the FY23 period, logging a huge growth in net profit after tax (NPAT) – but still eyes a sell-off.

The company’s profits for FY23 were at $92.5 million as opposed to $19.8 million in FY22, reflecting a corporate travel sector recovering from the COVID years.

EBITDA was also higher at $167.1 million for FY23 versus $59.8 million for FY22. The company held $151 million in cash at the end of the financial year and zero debt.

The company is paying a final dividend of 22 cents unfranked and expects to deliver record earnings per share (EPS) in FY24.

However, despite these strong results, investors sold off Corporate Travel Management stocks in the first leg of the trading day.

According to Australian financial publications, of possible concern to CTD’s investor base is its continued partnership with a UK entity to house refugees from Ukraine, Sudan and Afghanistan on a barge in English waters.

The Home Office contract is worth some $3 billion to Corporate Travel and its shareholders.

A group of NGOs and refugee advocate bodies recently wrote to Corporate Travels’ contract partner Bibby Marine, calling the move to house refugees in a floating barge is “cruel and inhumane.”

CTD shares were down 7.67 per cent, trading at $17.94 at 2:12 pm AEST.

CTD by the numbers
More From The Market Online
AI image of a lung cross section

4DX up another 15% on new demo delivery; now boasting $2.5B cap & no revenue

4DMedical has climbed to a lofty valuation just short of $4.80 on Wednesday, bringing the biotech…
Man holds Aus notes

4DMedical reportedly raising $150M at $3.80/sh; ASX 200 inclusion possible

4DMedical has startled some HotCopper forum users as it stages a $150 million capital raising at…

‘Significant advancement’ for Nova at RPM Valley with highest-grade drill results to date

Nova Minerals shared the highest-grade drill results to date at Estelle's RPM Valley deposit, marking a…

New Murchison sees Lydia prospect as perfect chance to add near-term resources to Crown Prince

New Murchison is working "quickly" to bring the Lydia gold prospect, complete with its high-grade results,…